an infectious agent. Mycoplasma pneumoniae stimulatesproduction of the interleukins and TNF-α and may be apotential cause of flare of BD, as described in this casereport.Case presentation: A 18-year-old Syrian male washospitalized with a 10-day history of dysphagia, fever,and impaired general condition. He had previously hadtwo episodes of oral aphthous ulcers healing sponta-neously. On admission, his white cell count was12.3 × 109/L, CRP 168 g/L, and body temperature38.9°C. He was treated with broad spectrum antibioticswith insignificant effect. He developed a severe flare ofBD in the form of genital/oral ulcers, rash, and conjunc-tivitis. Mycoplasma pneumoniae was confirmed by apositive serological test, and laboratory tests excludedherpes simplex virus, cytomegalovirus, Epstein–Barrvirus, varicella zoster, chlamydia, HIV, hepatitis, andsyphilis. Biopsy of the oral ulcer and scrotum showedunspecific inflammation. He was HLA-B52 positive.He was diagnosed as having BD based on recurrentoral/genital ulceration and eye lesions. Treatment withsystemic and local steroids resulted in clinical remission.Conclusion: Mycoplasma pneumoniae can be a triggerfor flare of BD, and should be taken into consideration,particularly in those with prolonged or recurrent epi-sodes of BD.

Reference

1. Criteria for diagnosis of Behçet’s disease. International StudyGroup for Behçet’s Disease. Lancet 1990;335:1078–80.

PP65

Rituximab-induced hypogammaglobulinaemia andintravenous immunoglobulin replacement therapy donot protect against relapse in granulomatous withpolyangiitis

E Besada

UiT The Arctic University of Norway, Norway

Background: Rituximab (RTX) is effective in inducingand maintaining remission in patients with granuloma-tous with polyangiitis (GPA). However, RTX decreasesserum levels of immunoglobulin (Ig) leading to hypo-gammaglobulinaemia and infections in some patients.This study aimed to examine the use of intravenousimmunoglobulin (IVIG) in GPA patients treated withRTX.Method: The study included 35 GPA patients from ourvasculitis registry who received long-term pre-emptiveRTX maintenance between April 2004 and June 2011.These patients (54% male) had a mean age of 50 (range14–81) years and had received 16 (0–250) g of cyclo-phosphamide. They also received an RTX cumulativedose of 9 (2–14) g and were followed up for 77 months.Hypogammaglobulinaemia was defined as total Ig< 6 g/L.Results: Nineteen patients (54%) developed hypogam-maglobulinaemia 33 (4–71) months after RTX initia-tion and RTX was readministered in 16 patients.Seven patients (20%) received IVIG 31 (0–43) monthsafter the diagnosis of hypogammaglobulinaemia. Twopatients discontinued IVIG after 3 and 4 months; how-ever, five patients were still on IVIG at the last visit,receiving 360 (150–390) g yearly in the past 3 years.Total Ig levels increased from 4.7 g/L before IVIG to7.4 g/L. Eight patients (23%) relapsed after 3 years ofRTX maintenance: five had hypogammaglobulinaemiaand four required IVIG. All three relapsing patientswith subglottic or endobronchial stenosis were on IVIG(p = 0.036).Conclusions: The risk of hypogammaglobulinaemia andthe need for IVIG increase during long-term RTX main-tenance in GPA. If treatment of hypogammaglobulinae-mia is required, IVIG use is usually prolonged. RTX-induced hypogammaglobulinaemia and IVIG do notprotect against relapse.

PP66

Enhanced compliance to osteoporosis prophylaxis inglucocorticoid (GC)-treated polymyalgia rheumatica(PMR) patients: the role of ongoing follow-up supportat nurse consultations

A Emamifar, SH Jakobsen, RG Mortensen, IMJ Hansen

Svendborg Hospital, Odense University Hospital, DenmarkFigure 1. Oral ulceration.

48 SCR 2016 – abstracts

www.scandjrheumatol.dk

Background: Compliance to osteoporosis prophylaxisin postmenopausal women has been described as verypoor; however, it is higher in patients with inflammatorydiseases treated with glucocorticoids (GCs), probablybecause of the risk of osteoporotic fractures as a side-effect of treatment (1).Objectives: To evaluate the adherence to osteoporosisprophylaxis in patients with polymyalgia rheumatica(PMR) who were treated with GCs and to investigatethe role of nurse consultations in enhancing complianceto treatment.Method: All patients diagnosed with PMR in 2013 wereinterviewed about their compliance towards osteoporosisprophylaxis using a standardized questionnaire. Patientswith mild disease were seen at every second consultationby a nurse specializing in rheumatology and were askedif they had remembered to take their prescribed medication.Results: Of the 118 included patients, 117 were pre-scribed calcium and vitamin D, and 88.9% of them tookthe medication as prescribed. The reasons for non-com-pliance were: forgetfulness, reluctance to take manypills, and side-effects. Bisphosphonates were prescribedin 61 patients and, of these, 96.6% took the medicationregularly. Non-compliance to bisphosphonates was in allcases due to gastrointestinal side-effects.Conclusions: Compliance will increase considerably ifthe nurses at every consultation ask about the prophy-lactic medications, at least in this group of patients witha very painful disease. Furthermore, a friendly atmo-sphere and emphasizing the importance of the medica-tion to prevent GC side-effects are both important.

Reference

1. Emamifar A, Gildberg-Mortensen R, Andreas Just S, Lomborg N,Asmussen Andreasen R, Jensen Hansen IM. Level of adherence toprophylactic osteoporosis medication amongst patients with poly-myalgia rheumatica and giant cell arteritis: a cross-sectional study.Int J Rheumatol 2015;2015:783709.

PainandfatigueinrheumaticdisordersPP67

Lower back pain as an initial symptom of a fatalinfection with leptospirosis

MM Søndergaard, A Tursunovic, P Thye-Rønn, IMJ Hansen

OUH, Svendborg Hospital, Denmark

A 45-year-old woman without prior medical history wasadmitted because of lower back pain radiating to the lefthip, fever, headache, nausea, and malaise. Two weeksbefore admission she was bitten by a rat and 2 days beforeadmission she contacted the doctor on call with severeback pain. Initially, her temperature was 39.7°C, bloodpressure 104/77 mmHg, and heart rate 132 beats/min.

A healed, non-infected scratch mark was found on herleft thigh. Physical examination was normal. Blood testsrevealed white blood cells 11.4 × 109/L, C-reactive protein288 mg/L, thrombocytes 59 × 109/L, haemoglobin7.2 mmol/L, creatinine 127 μmol/L, and erythrocyte sedi-mentation rate 51 mm/h. A chest X-ray showed diffusebilateral condensations, and renal ultrasound was normal.

Treatment with piperacillin/tazobactam and ciprofloxa-cin was initiated, and large quantities of intravenous fluidsto correct the electrolyte imbalance and hypotension.Eight hours after admission she desaturated to 80%despite maximum oxygen flow. Severe pulmonary hae-morrhage was observed, and shortly after, she went intocardiac arrest and died. Positive urine leptospiral DNAwas given post-mortem.Discussion: Leptospirosis, in Denmark most com-monly carried by rats, is generally mild, but it maycause tubulointerstitial nephritis, which can lead torenal failure. Leptospirosis can also lead to pulmon-ary haemorrhage and adult respiratory distress syn-drome. In Denmark, the incidence of leptospirosishas been steady since the early 1990s and has causedfour deaths between 1980 and 2012 (1).

Reference

1. van Alphen LB, Lemcke Kunoe A, Ceper T, Kahler J, Kjelso C,Ethelberg S, et al. Trends in human leptospirosis in Denmark,1980 to 2012. Euro Surveill 2015;20:pii:21019.

PP68

Effect of rehabilitation on health status and sleep inwomen with fibromyalgia

G Marteinsdottir, N Gudmundsdottir, I Kristjansson, H Bjarna-dottir, B Thorleifsdottir, M Guðjonsdottir

Reykjalundur Rehabilitation Centre, Iceland

Background: Fibromyalgia (FM) is a debilitating con-dition characterized by widespread chronic pain, fatigue,psychosocial stress, and disturbed sleep.Objectives: The aim of this study was to explore theeffect of a 6-week rehabilitation programme (6WR) onquality of sleep among FM patients compared to a groupof healthy controls.Method: Thirty-three women with FM entered thestudy but eight were excluded due to sleep apnoea.Twenty-five patients (mean age 46.8 ± 8.7 years) and12 matched controls (mean age 50.0 ± 8.4 years) com-pleted the Fibromyalgia Impact Questionnaire (FIQ),the Insomnia Severity Index (ISI), and the Dysfunc-tional Beliefs and Attitudes about Sleep (DBAS) ques-tionnaire and answered two questions rating thequality of their sleep (0–10) pre- and post-6WR orequal control period.Results: The results are presented in the following table.

SCR 2016 – abstracts 49

www.scandjrheumatol.dk

Conclusions: Sleep apnoea is common among FMpatients. Health status, beliefs, attitudes, and quality ofsleep are impaired in FM patients compared to controls.However, they improved significantly during the rehabi-litation programme in our study.

PP69

The impact of concomitant fibromyalgia on diseaseactivity composite indices in rheumatoid arthritis

J Toms, P Bradna, T Soukup, Z Hrncir

Charles University, Faculty of Medicine and University Hospi-tal, Czech Republic

Objectives: To examine the impact of fibromyalgia(FM) on disease activity composite indices (DAS-28,SDAI, CDAI) in patients with rheumatoid arthritis(RA) in a regional, monocentric, cross-sectionalstudy.Method: The same rheumatologist conductedan examination of 120 patients (29 males, 91females) with RA for the presence of concomitantFM according to the 1990 ACR criteria and anassessment of tender joint count (TJC), swollenjoint count (SJC), and tender point count (TPC).Laboratory parameters included erythrocyte sedimen-tation rate (ESR), C-reactive protein (CRP), rheuma-toid factor (RF), and anti-citrullinated peptideantibodies (ACPA).Results: The diagnosis of FM was established in 25(20.8%) patients with RA (RAF), four men and 21women. RA and RAF patients did not differ signifi-cantly in sociodemographic characteristics, laboratoryinflammatory markers, RF and ACPA seropositivity.RAF patients in comparison to RA patients obtainedsignificantly higher scores in all three compositeindices tested (DAS-28 5.35 ± 1.1 vs. 3.67 ± 1.4,p < 0.0001; SDAI 31.8 ± 10.9 vs. 13.5 ± 10.8,p < 0.0001; CDAI 29.6 ± 10.7 vs. 11.8 ± 9.4,p < 0.0001). Detailed analysis ascertained that TJCand patient’s VAS global health (GH) contributed

mostly to the disease activity differences; however,physician’s VAS GH was also significantly raised inRAF in comparison to RA.Conclusions: When using disease activity indices in clin-ical practice or in clinical trials, rheumatologists shouldtake into account the limitations that may arise when theindices do not in fact mirror inflammatory activity butmay be skewed by measurements dependent on an indi-vidual patient’s pain perception.

PP70

Effect of 6 weeks of rehabilitation on health status, stress,anxiety, and depression in women with fibromyalgia

I Kristjansson1, GL Marteinsdottir1, NK Gudmundsdottir1,H Bjarnadottir1, B Thorleifsdottir2, M Gudjonsdottir2

1Reykjalundur Rehabilitation Centre, Iceland, 2University of Ice-land, Iceland

Objectives: Fibromyalgia (FM) is a debilitating condi-tion characterized by widespread chronic pain, fatigue,psychosocial stress, and depleted exercise tolerance.The aim of this study was to explore the effect of a6-week rehabilitation programme (6WR) on health sta-tus and psychological well-being among femalepatients with FM compared to a group of healthyfemale controls.Method: Twenty-five women with FM (mean age46.8 ± 8.7 years) and 12 matched controls (meanage 50.0 ± 8.4 years) completed the FibromyalgiaImpact Questionnaire (FIQ) and the Depression,Anxiety and Stress Scale (DASS) pre- and post-6WR or an equal control period. Their functionalexercise capacity was measured by the 6-minute walktest (6MWT).Results: The results are shown in the following table.Conclusions: Health status, functional exercise capacity,and psychological well-being are impaired among FMpatients compared to controls. However, they improvedsignificantly during the rehabilitation programme in ourstudy.

Fibromyalgia patients (n = 25) Control group (n = 12)

Pre-6WR Post-6WR Pre-control period Post-control period

BMI (kg/m2) 31.6 ± 5.3 31.0 ± 4.8 29.1 ± 4.2 29.1 ± 4.3FIQ total score 59.1 ± 12.3 42. 5 ± 12.4* 5.1 ± 5.8†ISI score 16.0 ± 5.0 14.4 ± 4.3* 3.2 ± 3.7† 2.9 ± 2.8DBAS score 94.8 ± 26.1 52.1 ± 17.8†Subjective sleep quality 5.5 ± 1.1 6.2 ± 1.4* 8.3 ± 0.8† 8.2 ± 0.8Subjective sleep refreshment 4.8 ± 1.2 5.4 ± 1.5 8.6 ± 0.8† 8.3 ± 0.7

BMI, Body Mass Index; FIQ, Fibromyalgia Impact Questionnaire (FIQ); ISIm, Insomnia Severity Index; DBAS, Dysfunctional Beliefsand Attitudes about Sleep.*p < 0.05 post- vs. pre-6WR in the FM group. †p < 0.005 controls pre- vs. patients pre- data.

50 SCR 2016 – abstracts

www.scandjrheumatol.dk

PP71

A description and study of a physiotherapy residentialprogramme for Scandinavian patients with rheumaticdiseases

BB Braulio

Kinesis, Spain

The main clinical manifestations of rheumatic diseasesare inflammation of the joints, morning stiffness, andpain, and these events affect the patients’ quality ofsleep and consequently their quality of life. Havingaccount of the functional impact resulting from thesechanges, our study hypothesis was that the performanceof a specific treatment of physiotherapy in rheumaticpatients could achieve positive results with regard topain, improving quality of sleep and reducing morningstiffness, and consequently affecting positively bothphysical and psychological well-being. To demonstratethis, our study aimed to evaluate the effectiveness of aprogramme of physical therapy using different variablesrelated to pain and physical (sleep quality and morningstiffness) welfare. Based on the initial hypothesis, themain objectives of the study were to demonstrate theeffectiveness of the programme of physical therapy inpatients suffering from various rheumatic diseases, andto compare the results between the day when treatmentbegan and the last day of treatment, also comparison bygender, relying on measurements of certain variables,taken before and after the treatment programme.

The Physical Therapy Programme that we apply isbased primarily on the use of soft gymnastics. We con-sider these to be of benefit to patients suffering fromrheumatic diseases. The programme comprises hydro-therapy, manual therapy, occupational therapy, and indi-vidual teaching of specific exercises. Specific objectivesare to improve functionality (improvement of pain),enhance the quality of life of these patients, and slowthe degenerative disease process by establishing a pro-gramme of exercise and self-care for rheumatic diseases,which can also be carried out at home.

PP72

Study of the reparation of the rotator cuff by combiningscaffolds with BMP-2

C Arvinius1, Y Lopiz1, MC Rodriguez-Bobada2, A Civantos3,M Diaz-Moreno4, P Dolz-Gaitón4, F Marco2

1Department of Orthopaedic Surgery and Traumatology, Hos-pital Clinico San Carlos, Spain, 2Experimental Medicine andSurgery Unit, Hospital Clinico San Carlos, Spain, 3CSIC, Spain,4Charles III University of Madrid, Spain

Background: Therapeutic suturing of chronic rotatorcuff tears presents an elevated percentage of re-rupture.The failure of tendon-to-bone regeneration could berelated to the absence of appropriate molecular signal-ling and cell differentiation. Tissue engineering couldtherefore be an alternative to increasing the mechanicalstrength of the suture. The aim of this study was toevaluate the benefits of scaffolds alone and in combina-tion with recombinant human bone morphogenetic pro-tein-2 (rhBMP-2) in the healing process of chronictendon-to-bone tears in an experimental model. At thesame time a rat model with chronic rotator cuff lesions isdescribed for further investigation.Method: Forty rats underwent unilateral supraspinatustendon section. Four weeks later a transosseous suturewas performed in association with scaffolds of alginate,chitosan, and rhBMP-2. According to the scaffold used,the rats were divided into four groups. Four months afterthe reparation the rats were killed and histological andbiomechanical studies performed.

Fibromyalgia patients (n = 25) Control group (n = 12)

Pre-6WR Post-6WR Pre- Post-

BMI (kg/m2) 31.6 ± 5.3 31.0 ± 4.8 29.1 ± 4.2 29.1 ± 4.3FIQ score 59.1 ± 12.3 42.5 ± 12.4* 5.1 ± 5.8†DASS depression 10.3 ± 6.9 6.3 ± 6.5* 1.0 ± 1.2† 1.1 ± 1.7DASS anxiety 8.0 ± 6.3 6.0 ± 5.8 1.4 ± 2.6† 0.8 ± 1.9DASS stress 12.2 ± 5.9 9.4 ± 7.0 2.6 ± 3.2† 2.8 ± 3.46MWT (m) 564 ± 58 584 ± 63* 659 ± 45† 666 ± 356MWT (% predicted) 86 ± 10 103 ± 6†

*p < 0.05 post-6WR vs. pre-6WR in the group. †p < 0.005 controls pre- vs. patients pre- data.

SCR 2016 – abstracts 51

www.scandjrheumatol.dk

Results: In the second surgery all cases presented anosteotendinous gap, simulating chronic rotator cufflesions in humans. A favourable reparation was per-formed in all cases but three, where the reparation hadto be performed with a tensioned suture. Histologicalanalysis revealed three re-ruptures and two cases pre-sented ruptured sutures with a repaired tendon. Thestrength and rigidity were highest in the alginate+chit-osan group while the elasticity was best with alginate+rhBMP-2 and chitosan+rhBMP-2.Conclusions: Bioactive scaffolds in combination withrhBMP-2 seem to increase the elasticity and resistanceof tendon sutures. They could thereby be important instimulating the biological regeneration of the rotator cuff.Figure 1. Macroscopic and microscopic visualization of the tendon repair.

52 SCR 2016 – abstracts

www.scandjrheumatol.dk

Author IndexAbdwani R, 46Aftab O, 44Aga A-B, 12Aga A-B, 16Ahlehoff O, 36Ahmetaj-Shala B, 24Ainola M-M, 44Albrecht I, 8Al Chaer N, 3Aleksandra A, 45Alenius G-M, 29Alfredsson L, 19Allaart R, 19Alonso RB, 20Al Thuhli K, 46Al Zuhaibi S, 46Amara K, 10Amara K, 11Ancuta I, 15Andersen BL, 4Andersen LS, 3Andersen LS, 4Andreasen RA, 28Andreasen RA, 47Antonsen S, 28Antovic A, 45Arnaud L, 40Arnaud L, 41Arnaud L, 42Arnaud L, 43Arora V, 8Artacho A, 5Arvidsson L, 16Arvinius C, 51Askling J, 1Askling J, 19Augendre-Ferrante B, 21Baek S-Y, 44Bakland G, 35Beaart-van de Voorde L, 36Beattie SD, 22Berg L, 44Berg L, 45Bergquist M, 11Bergqvist F, 44Bergström U, 16Besada E, 48Beselin A, 21Bjarnadottir H, 49Bjarnadottir H, 50Bjoerndal K, 18Bjorgulfsson TM, 25Blondal T, 25Bokarewa M, 12Bollen E, 36Bolstad N, 6Book C, 14Boyle DL, 30Bradna P, 50Bratt S, 12Braulio BB, 51Brismar K, 6Brokstad KA, 12Burson JS, 21Camponeschi A, 11Cañete J, 33Cañete J, 35Canhão H, 15Carlsson L, 7Casillas M, 20Casillas M, 21Catrina A, 5Catrina A, 10Catrina AI, 10

Catrina AI, 11Catrina SB, 10Chapman D, 19Chatzidionysiou K, 10Chatzidionysiou K, 15Chatzidionysiou K, 64Chen G, 24Christensen SR, 3Chrysidis S, 4Civantos A, 51Colic A, 4Combe B, 21Conaghan P, 33Conaghan P, 35Connell C, 20Cordtz R, 27Coskun S, 45Cuchacovich R, 31Curran M, 24Danielsen L, 3Davenport E, 33De Bono S, 8De la Torre I, 20DeMasi R, 19DeMasi R, 20Deodhar A, 35Diamantopoulos AP, 33Diaz-Moreno M, 51Ding H, 40Ding H, 42Ding H, 43Dolz-Gaitón P, 51Dougados M, 20Drevets W, 24Dreyer L, 3Dreyer L, 8Dreyer L, 27Dreyer L, 30Dreyer L, 36Ejstrup L, 33Eketj ll S, 39Elvin K, 45Emamifar A, 9Emamifar A, 16Emamifar A, 18Emamifar A, 27Emamifar A, 28Emamifar A, 48Emery P, 20Emoto K, 8Enevold C, 6Eng G, 6Engström M, 10Eriksson J, 19Erlandsson M, 12Erlendsson K, 14Espesen J, 3Espesen J, 4Fallon L, 19Fathi M, 8Faurschou M, 37Fei K, 22Fei K, 23Fernandes-Cerqueira C, 8Fevang BTS, 12Fevang BTS, 18Fleischmann R, 22Førre Ø, 35Forslind K, 14Frederiksen BA, 3Frederiksen BA, 34Furnes O, 18Gabay C, 15Gaich C, 8

Gaillez C, 33Gandhi K, 35Geborek P, 46Gehin J, 6Gerhardsson J, 41Ghizdavescu AP, 20Gislason G, 36Gjertsson I, 11Gladman D, 31Glintborg B, 3Glintborg B, 4Glintborg B, 6Glintborg B, 30Goll G, 6Gomez-Reino J, 15Gossec L, 33Gossec L, 35Grondal G, 25Gröndal G, 14Grøn KL, 6Grunewald J, 5Grunewald J, 8Grunewald J, 10Grydehøj J, 4Gudbjornsson B, 9Gudbjornsson B, 25Gudbjornsson B, 30Gudbjornsson B, 31Gudbjornsson B, 33Gudmundsdottir N, 49Gudmundsdottir NK, 50Guðjonsdottir M, 49Guðjonsdottir M, 50Guðmundsson HT, 9Gunnarsdóttir AI, 31Gunnarsson I, 4Gunnarsson I, 38Gunnarsson I, 39Gunnarsson I, 40Gunnarsson I, 41Gunnarsson I, 42Gunnarsson I, 43Gunnarsson K, 46Gunnarsson PS, 31Gurbuz S, 22Gustafsson J, 38Gustafsson JT, 4Gustafsson JT, 39Gustafsson M, 44Häanninen A, 44Haavardsholm EA, 12Haavardsholm EA, 16Hai van Bui Hansen M, 9Hakala M, 25Halldorsson BV, 9Halse A-K, 13Hambardzumyan K, 6Hammer HB, 12Hammer HB, 13Hammer HB, 33Hansen IM, 35Hansen IMJ, 2Hansen IMJ, 3Hansen IMJ, 4Hansen IMJ, 6Hansen IMJ, 9Hansen IMJ, 16Hansen IMJ, 17Hansen IMJ, 18Hansen IMJ, 27Hansen IMJ, 28Hansen IMJ, 34Hansen IMJ, 47Hansen IMJ, 48

Hansen IMJ, 49Hansen KE, 9Hansen MB, 9Hansen MB, 27Hansson M, 10Hansson M, 19Haugeberg G, 29Haugeberg G, 30Haugeberg G, 33Hauge E, 15Haugen IK, 58Havelin LI, 18Hendricks O, 3Hendricks O, 4Hendricks O, 6Hensvold AH, 10Hermansen M-LF, 37Hesselvig JH, 36Hetland M, 15Hetland ML, 3Hetland ML, 4Hetland ML, 6Høgdall E, 6Højgaard P, 30Holmdahl R, 19Holmqvist M, 1Hrncir Z, 50Hsu B, 22Hsu B, 23Hsu B, 24Huizinga T, 2Huizinga T, 36Hwang L-J, 19Idborg H, 4Idborg H, 39Irto I, 20Ishii T, 8Iversen L, 33Jacobsen S, 37Jacobsen S, 38Jacobsson L, 11Jacobsson L, 14Jacobsson L, 16Jakobsen SH, 48Jakobsson P-J, 4Jakobsson P-J, 8Jakobsson P-J, 24Jakobsson P-J, 39Jakobsson P-J, 44Jensen DV, 4Jensen DV, 6Jeon H, 44Johannesson M, 19Johansen JS, 6Jönsson G, 46Jonsson MK, 12Joshua V, 5Joshua V, 10Joshua V, 11Jugl S, 33Jugl S, 35Ju JH, 44Juneblad K, 29Jung M-K, 44Just SA, 34Kapetanovic MC, 46Karpouzas G, 22Karpouzas G, 23Kauppi E, 25Kavanaugh A, 29Kavanaugh A, 30Kavanaugh A, 33Keystone E, 19Keystone EC, 8

Scand J Rheumatol 2016;45 Suppl 128:76–77 76

www.scandjrheumatol.dk

Kim H, 44Kim SH, 44Kirkby N, 24Kjµr L, 38Klareskog L, 19Klarlund M, 4Knudsen JB, 47Kofoed K, 36Koh JH, 44Konttinen Y, 44Korotkova M, 24Kowalski MR, 3Kragstrup TW, 53Kraus DGA, 3Kringelbach T, 6Krishnamurthy A, 11Kristensen LE, 30Kristensen S, 4Kristjansdottir H, 14Kristjansson I, 49Kristjansson I, 50Krogh NS, 3Krogh NS, 4Krogulec M, 20Kruyt N, 36Kultima K, 44Kuo W-L, 22Kurrasch R, 23Kvarnström M, 39Kvien T, 15Kvien TK, 12Kvien TK, 16Kvien TK, 33Kvien TK, 35Kwok K, 20Kwok S-K, 44Laasonen L, 33Larsson E, 8Larsson E, 20Larsson E, 21Larsson E, 22Larsson E, 31Larsson R, 44Laursen B, 27Lazariciu I, 20Lee CH, 31Lee EB, 19Lee EB, 20Lee J, 44Lengqvist J, 8Lengqvist J, 44Levitsky A, 6Lie E, 15Lillegraven S, 12Lillegraven S, 16Linauskas A, 4Lin C-Y, 31Lindegaard HM, 4Lindhardsen J, 37Lindqvist U, 33Liu B, 24Ljung L, 1Locht H, 27Loft AG, 3Loft AG, 4Loft AG, 6Lopiz Y, 51Lourdudoss C, 6Love TJ, 30Love TJ, 31Ludviksson BR, 9Lukina G, 15Lundberg I, 45Lundberg IE, 88Macias WL, 8Macias WL, 22Maglio C, 7Magro C, 36Magyari M, 27Malmström V, 10

Malmström V, 11Malmström V, 41Manilo N, 4Marco F, 51Marteinsdottir G, 49Marteinsdottir GL, 50Martin R, 3Marzo-Ortega H, 3Mathsson- L Alm,McInnes I, 19Mease P, 31Menno H, 36Michelsen B, 29Michelsen B, 30Michelsen B, 33Middelkoop H, 36Min HK, 44Mitchell J, 24Mjaavatten MD, 16Mobarrez F, 38Mohamoud AA, 3Mohan C, 40Mohan C, 42Mohan C, 43Mortensen RG, 48Mousavi S, 9Mousavi S, 27Mpofu S, 33MRes SM, 24Mσrtensson I-L, 11Nagel J, 46NÇasman L, 45Nduaka C, 20Nielsen CH, 6Nielsen CH, 38Nikiphorou Em 25Nilsson J-Å, 14Nilsson J-Å, 16Nilsson P, 4Nived P, 46Nordal HH, 12Nordal HH, 13Nordin AÅH, 45Nordin AÅH, 46Nordin H, 3Nordin H, 4Nordström D, 15Nordström D, 44Norkko J, 45Notarnicola A, 8Notarnicola A, 45Nyren S, 46Nystad TW, 18Oke V, 39Olsen IC, 12Olsen IC, 16Olsen J, 4ØM, 35Ospelt C, 10Ossipova E, 8Ossipova E, 44Østergaard M, 3Østergaard M, 21Østergaard M, 33Paimela L, 33Park S-H, 44Parodis I, 40Parodis I, 41Parodis I, 42Parodis I, 43Pavelka K, 15Pedersen JK, 3Pelck R, 3Pettersson S, 39Pikwer M, 16Pirilä L, 25Pisetsky D, 38Porola P, 44Pruijn GJ, 8Przybyla B, 44

Pullerits R, 12Puolakka K, 25Raeman F, 20Rantapää-Dahlqvist S, 29Rao R, 22Raouf J, 24Raun JL, 3Rentero ML, 20Rethi B, 10Rethi B, 11Reynisdottir G, 10Richards H, 3Richards H, 35Ritchlin C, 31Rodriguez-Bobada MC, 51Rönnelid J, 8Rönnelid J, 19Rooney T, 8Rooney T, 22Rossini M, 20Rubin J, 44Rudin A, 7Runarsdottir E, 31Rydell E, 14Saevarsdottir S, 6Saevarsdottir S, 15Saevarsdottir S, 19Salomonsen L, 3Salvadore G, 24Samanta S, 31Saparamadu A, 46Saxne T, 46Scherer U, 2Scher J, 5Schiff M, 22Schlemmer A, 3Schlichting D, 8Schlichting DE, 22Segal L, 5Sellebjerg F, 27Serre G, 10Serre G, 19Sheng S, 22Sheng S, 23Shuler C, 31Sieper J, 3Silverfield J, 20Singh J, 24Skattum L, 46Skriner K, 19Smolen J, 21Sohrabian A, 8Sokka-Isler T, 3Sokka T, 25Soldal DM, 29Soldal DM, 30Soldal DM, 33Solomon DH, 16Søndergaard MM, 49Sørensen IJ, 3Sørensen IJ, 4Sørensen IJ, 6Sørensen MV, 4Soukup T, 50Steinsson K, 14Steup-Beekman G, 36Stoykov I, 22Stride PJO, 9Stσhle M, 33Sundelin B, 41Sundlisæter NP, 16Sundström M, 44Sundström Y, 44Sun M, 10Sun M, 11Sun Y, 24Svenungsson E, 4Svenungsson E, 38Svenungsson E, 39Svenungsson E, 41

Svenungsson E, 42Svenungsson E, 45Svenungsson E, 46Tahir H, 21Taimen K, 25Takakubo Y, 44Takeuchi T, 22Takeuchi T, 23Tanaka Y, 8Tang Q, 45Tarasova N, 11Taylor P, 8Ternowitz T, 33Thorarinsdottir K, 11Thorleifsdottir B, 49Thorleifsdottir B, 50Thorne C, 22Thorne C, 23Thye-Rønn P, 49Tjärlund A, 45Toes R, 2Toftegaard P, 17Tolvanen T, 44Tomsic M, 15Toms J, 50Tony H-P, 21Torp-Pedersen C, 37Trouw L, 2Turesson C, 14Turesson C, 16Turkkila M, 12Tursunovic A, 49Ubeda C, 5Uhlig T, 16van Buchem M, 36van Bui Hansen MH, 27van Bui Hansen MN, 28van der Heijde D, 8van der Heijde D, 31van der Helm A, 2van der Wee N, 36van derWoude D, 19Vangerow H, 31van Vollenhoven R, 6van Vollenhoven R, 15van Vollenhoven R, 19van Vollenhoven RF, 19Velander MJ, 3Velander MJ, 34Vikerfors A, 38Wähämaa H, 10Wähämaa H, 11Walker D, 20Wallén H, 38Wang D, 24Wang L, 20Warren DJ, 6Weinblatt ME, 8Wilkinson B, 19Williams N, 35Wittenberg G, 24Wollenhaupt J, 20Xu S, 23Xu W, 22Xu W, 23Yang L, 8Yoo JH, 44Ytterberg J, 11Zamani O, 21Zandian A, 4Zeldin D, 24Zhou Y, 24Zickert A, 38Zickert A, 39Zickert A, 40Zickert A, 41Zickert A, 42Zickert A, 43Zirkzee E, 36

77 Author Index

www.scandjrheumatol.dk